MHLW Panel Tables Decision on Efient’s Preventive Use for ICD Recurrences; Lilly's Migraine Med, Jardiance's Heart Failure Indication OK'ed

November 9, 2021
A key health ministry panel on November 5 held off on backing approval for Daiichi Sankyo’s antiplatelet agent Efient (prasugrel) for a new indication of preventing the recurrence of ischemic cerebrovascular disease (ICD), while giving the go-ahead to other medicines...read more